Exception code: 126
Exception message:
Incorrect key file for table '/tmp/#sql_7f1_23.MYI'; try to repair it

Thrown by: '/home/usmoz/public_html/lib/dbcontroller/DbMysql.class.php'
on line: '184'.

Stack trace:
#0 /home/usmoz/public_html/lib/dbcontroller/DbMysql.class.php(62): DbMysql->throwMysqlException()
#1 /home/usmoz/public_html/lib/dbcontroller/DbControl.class.php(104): DbMysql->query('SELECT r.rep_na...')
#2 /home/usmoz/public_html/lib/dbcontroller/DbControl.class.php(212): DbControl->initiate()
#3 /home/usmoz/public_html/Model/Report.cls.php(164): DbControl->GetAll('SELECT r.rep_na...')
#4 /home/usmoz/public_html/report.php(80): Reports->getUpcomingReports()
#5 {main}
China Large Volume Parenteral (LVP) Industry Report, 2013-2015 Market, Trends, Share, Size Research Report

ResearchMoz

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Research In China
Published Date » 2013-11-29
No. Of Pages » 65
   
 Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese preparations have grown year by year. In 2006-2012, China’s injection output presented the CAGR of 19.2%. However, due to the low barriers to entry, China has seen some signs of the surplus injection capacity, which exceeds the demand by roughly 40%. 
   
 Overcapacity and fierce competition are caused by the irrational injection product structure and homogeneity. For example, the output and sales volume of fluid balance injection products with low added value account for 89% of the injection market, but the sales revenue only shares 47%. At the same time, the market demand for...
TABLE OF CONTENT

1 Overview of LVP
1.1 Definition and Classification
1.2 Industry Chain

2 Overview of China LVP Industry Development
2.1 Status Quo
2.2 Competition Pattern
2.3 Product Structure
2.4 Regional Distribution
2. 5 Development Forecast 

3 Chinese LVP Market Segments
3.1 Injection for Fluid Balance
3.2 Therapeutic Injection
3.3 Nutritious Injection
3.3.1 Fructose Injection
3.3.2 Amino Acid Injection
3.3.3 Fat Emulsion Injection
3.4 Injection for Blood Volume Expansion 
3.4.1 Dextran Injection
3.4.2 Hydroxyethyl Starch Injection
3.5 Peritoneal Dialysis Solution

4 Main Companies
4.1 Kelun Pharma 
4.1.1 Profile 
4.1.2 Operation 
4.1.3 Revenue Structure 
4.1.4 Gross Margin 
4.1.5 Clients and Suppliers 
4.1.6 R & D and Investment
4.1.7 LVP Business 
4.1.8 Development Forecast 
4.2 China Resources Double-Crane 
4.2.1 Profile 
4.2.2 Operation 
4.2.3 Revenue Structure 
4.2.4 Gross Margin 
4.2.5 Major Clients 
4.2.6 LVP Business 
4.2.7 Development Forecast 
4.3 Fengyuan Pharmaceutical  
4.3.1 Profile 
4.3.2 Operation 
4.3.3 Revenue Structure 
4.3.4 Gross Margin 
4.3.5 Clients and Suppliers 
4.3.6 LVP Business 
4.3.7 Development Forecast 
4.4 Huaren Pharmaceutical
4.4.1 Profile 
4.4.2 Operation 
4.4.3 Revenue Structure 
4.4.4 Gross Margin 
4.4.5 Clients and Suppliers 
4.4.6 R & D and Investment
4.4.7 Development Forecast 
4.5 Southwest Pharmaceutical 
4.5.1 Profile 
4.5.2 Operation 
4.5.3 Revenue Structure 
4.5.4 Gross Margin 
4.5.5 Major Clients 
4.5.6 LVP Business 
4.5.7 Development Forecast 
4.6 Lijun International Pharmaceutical (Holding)
4.6.1 Profile
4.6.2 Operation 
4.6.3 Shijiazhuang No.4 Pharmaceutical 
4.7 Other Companies
4.7.1 Qingzhou Yaowang Medicine 
4.7.2 Jilin Dubang Pharmaceutical 
4.7.3 Shandong Lukang Cisen Pharmaceutical  
4.7.4 China Otsuka Pharmaceutical 

List of Tables

NA

List of Figures

NA

Upcoming Reports:

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Motor Co.s Shares Suffer Downfall as Lower Profit Outlook for 2014-2015 Surface
Oct 1, 2014  
Suffering from higher recall costs in its North American market and great losses in South America and Russia have made Ford motor Co. to cut-down its forecast regarding pretax profit this year to $6 billion from $7 billion to $8 billion as earlier mentioned.  Company’s CFO Bob Shanks said that company’s pretax profit in 2015 is expected to rise between $8.5 and $9.5...
Evereadys Kenya Plant to be Shut Down
Sep 30, 2014  
The largest dry-cell battery manufacturer in the region of East Africa, Eveready East Africa Ltd. intends on shutting down its one and only factory in Kenya on the 1st of October 2014. A real estate business will be started in its place. According to the Managing Director of Eveready East Africa Ltd. the plan of shutting down the plant was initiated by the board members of this company...
Sale of Apples iPhones Remains Unaffected - Supported By Consumer Feedback
Sep 29, 2014  
iPhones have been reintroduced in the global market by Apple Inc. in about 22 countries. Consumer reports and feedback basically show that due to the presence of a problem-free backing and update, these handsets are sturdy and do not bend easily. It has been observed via stress tests conducted on iPhone 6 and 6 Plus, that it requires high force and pressure to cause damage to these...
New Malware Targets Pharma Servers
Sep 29, 2014  
The electronics and communication agency Beldon has reportedly spotted a new cyber threat to the pharmaceutical industry. Called Dragonfly, the malware specifically targets intellectual property of servers in the pharmaceutical industry with the purpose of stealing information. An initial report released by ipprolifesciences.com stated the malware was targeting the energy sector....
Child’s Success Depends on Father’s Education Level: Study
Sep 24, 2014  
A father’s level of education is the strongest attribute that can determine a child’s success in academics, according to a research conducted in Britain. It also says that there is a self-reinforcing cycle of lack of achievement and poverty that is handed down from parent to child. The report was released by the Office for National Statistics and states that children are...